WOCKPHARMA

Wockhardt Share Price

₹1,247.00 -92.6 (-6.91%)

22 Jan, 2025 12:35

SIP TrendupStart SIP in WOCKPHARMA

Start SIP

Performance

  • Low
  • ₹1,236
  • High
  • ₹1,374
  • 52 Week Low
  • ₹415
  • 52 Week High
  • ₹1,583
  • Open Price₹1,374
  • Previous Close₹1,340
  • Volume489,778

Investment Returns

  • Over 1 Month -14.26%
  • Over 3 Month + 16.91%
  • Over 6 Month + 60.56%
  • Over 1 Year + 177.85%
SIP Lightning

Smart Investing Starts Here Start SIP with Wockhardt for Steady Growth!

Invest Now

Wockhardt Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -70.3
  • PEG Ratio
  • -1.6
  • Market Cap Cr
  • 20,260
  • P/B Ratio
  • 6
  • Average True Range
  • 64
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • 5.26
  • RSI
  • 43.75
  • MFI
  • 39.38

Wockhardt Financials

Wockhardt Technicals

EMA & SMA

Current Price
₹1,247.00
-92.6 (-6.91%)
pointer
  • stock-down_img
  • Bearish Moving Average 11
  • stock-up_img
  • Bullish Moving Average 5
  • 20 Day
  • ₹1,400.48
  • 50 Day
  • ₹1,354.61
  • 100 Day
  • ₹1,230.21
  • 200 Day
  • ₹1,024.84

Resistance and Support

1352.5 Pivot Speed
  • R3 1,447.75
  • R2 1,420.30
  • R1 1,379.95
  • S1 1,312.15
  • S2 1,284.70
  • S3 1,244.35

What's your outlook on Wockhardt?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Wockhardt Ltd. is a global pharmaceutical and biotechnology company specializing in the development, manufacturing, and marketing of medicines, vaccines, and biosimilars. It focuses on key therapeutic areas including anti-infectives, cardiology, and diabetes care.

Wockhardt has an operating revenue of Rs. 2,949.00 Cr. on a trailing 12-month basis. An annual revenue growth of 4% is not great, Pre-tax margin of -15% needs improvement, ROE of -13% is poor and needs improvement. The company has a reasonable debt to equity of 27%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 45% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 41 which is a POOR score indicating inconsistency in earnings, a RS Rating of 93 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 55 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of A is the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Wockhardt Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Quarterly Results
2024-08-09 Quarterly Results
2024-05-28 Audited Results
2024-03-26 Others Inter alia, to consider and determine the issue price of Equity Shares to be issued pursuant to the Issue, including any discount, not more than 5%, on the floor price. issue of equity shares of Rs. 5/- each in the ratio of 3:10 @ premium of Rs. 220/-.
2024-02-14 Quarterly Results

Wockhardt F&O

Wockhardt Shareholding Pattern

51.99%
2.95%
0%
6.7%
0%
29.02%
9.34%

About Wockhardt

  • NSE Symbol
  • WOCKPHARMA
  • BSE Symbol
  • 532300
  • Managing Director
  • Dr. Murtaza Khorakiwala
  • ISIN
  • INE049B01025

Similar Stocks to Wockhardt

Wockhardt FAQs

Wockhardt share price is ₹1,247 As on 22 January, 2025 | 12:21

The Market Cap of Wockhardt is ₹20260.3 Cr As on 22 January, 2025 | 12:21

The P/E ratio of Wockhardt is -70.3 As on 22 January, 2025 | 12:21

The PB ratio of Wockhardt is 6 As on 22 January, 2025 | 12:21

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23